Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care

Clicks: 534
ID: 110322
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #12 of 128 articles by views in malaria journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 128 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
An effective malaria vaccine, deployed in conjunction with other malaria interventions, is likely to substantially reduce the malaria burden. Efficacy against severe malaria will be a key driver for decisions on implementation. An initial study of an RTS, S vaccine candidate showed promising efficacy against severe malaria in children in Mozambique. Further evidence of its protective efficacy will be gained in a pivotal, multi-centre, phase III study. This paper describes the case definitions of severe malaria used in this study and the programme for standardized assessment of severe malaria according to the case definition. Case definitions of severe malaria were developed from a literature review and a consensus meeting of expert consultants and the RTS, S Clinical Trial Partnership Committee, in collaboration with the World Health Organization and the Malaria Clinical Trials Alliance. The same groups, with input from an Independent Data Monitoring Committee, developed and implemented a programme for standardized data collection. The case definitions developed reflect the typical presentations of severe malaria in African hospitals. Markers of disease severity were chosen on the basis of their association with poor outcome, occurrence in a significant proportion of cases and on an ability to standardize their measurement across research centres. For the primary case definition, one or more clinical and/or laboratory markers of disease severity have to be present, four major co-morbidities (pneumonia, meningitis, bacteraemia or gastroenteritis with severe dehydration) are excluded, and a Plasmodium falciparum parasite density threshold is introduced, in order to maximize the specificity of the case definition. Secondary case definitions allow inclusion of co-morbidities and/or allow for the presence of parasitaemia at any density. The programmatic implementation of standardized case assessment included a clinical algorithm for evaluating seriously sick children, improvements to care delivery and a robust training and evaluation programme for clinicians. The case definition developed for the pivotal phase III RTS, S vaccine study is consistent with WHO recommendations, is locally applicable and appropriately balances sensitivity and specificity in the diagnosis of severe malaria. Processes set up to standardize severe malaria data collection will allow robust assessment of the efficacy of the RTS, S vaccine against severe malaria, strengthen local capacity and benefit patient care for subjects in the trial. Clinicaltrials.gov NCT00866619
Reference Key
vekemans2011malariaassessment Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Johan Vekemans;Kevin Marsh;Brian Greenwood;Amanda Leach;William Kabore;Solange Soulanoudjingar;Kwaku Poku Asante;Daniel Ansong;Jennifer Evans;Jahit Sacarlal;Philip Bejon;Portia Kamthunzi;Nahya Salim;Patricia Njuguna;Mary J Hamel;Walter Otieno;Samwel Gesase;David Schellenberg;Johan Vekemans;Kevin Marsh;Brian Greenwood;Amanda Leach;William Kabore;Solange Soulanoudjingar;Kwaku Poku Asante;Daniel Ansong;Jennifer Evans;Jahit Sacarlal;Philip Bejon;Portia Kamthunzi;Nahya Salim;Patricia Njuguna;Mary J Hamel;Walter Otieno;Samwel Gesase;David Schellenberg;
Journal malaria journal
Year 2011
DOI
doi:10.1186/1475-2875-10-221
URL
http://dx.doi.org/10.1186/1475-2875-10-221
Keywords
Microbiology public health entomology infectious diseases tropical medicine parasitology National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't algorithms Child preschool Clinical Trial Phase III Multicenter Study severity of illness index kevin marsh malaria / diagnosis* mozambique pmid:21816031 pmc3221632 doi:10.1186/1475-2875-10-221 johan vekemans clinical trials partnership committee biomedical research / standards* data collection / standards* malaria / pathology* malaria vaccines / immunology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.